Ultrastructural analysis of bone marrow hematopoiesis in mice transgenic for the thymidine kinase gene driven by the alpha IIb promoter.
Transgenic mice have been generated with expression of the herpes virus thymidine kinase gene directed by a 2.7-kb fragment of the alphaIIb murine promoter of the gene encoding the alphaIIb-subunit of the platelet integrin alphaIIbbeta3 (Tropel et al, Blood 90:2995, 1997). Administration of ganciclovir (GCV) to these mice resulted not only in an acute cessation of platelet production due to the depletion of the megakaryocytic lineage, but also a decrease in erythrocyte and leukocyte numbers. Immunogold staining on ultrathin frozen sections and electron microscopy has now shown that the remaining population of immature hematopoietic cells contain a high proportion of Sca-1(+) and CD34(+) cells, with CD45R+ cells of the lymphopoietic lineage being maintained. Stromal cells were also preserved. Blood thrombopoietin levels were high. At 4 days of the recovery phase, Sca-1 and CD34 antigen expression decreased with intense proliferation of cells of the three lineages, with megakaryocyte (MK) progenitors being identified by their positivity for glycoprotein IIb-IIIa. These results suggest that transcriptional activity for the alphaIIb gene promoter was present on pluripotent hematopoietic stem cells. At 6 to 8 days after cessation of GCV, numerous mature MK were observed, some of them with deformed shapes crossing the endothelial barrier through thin apertures. Proplatelet production was visualized in the vascular sinus. After 15 days, circulating platelet levels had increased to approximately 65% of normal. Transgenic alphaIIb-tk mice constitute a valuable model to study in vivo megakaryocytopoiesis.
Poujol
C
C
UMR 5533 CNRS, Hôpital Cardiologique, Pessac, France; and the Laboratoire de Transgénèse et de Différenciation Cellulaire du CEA, Grenoble, France.
Tronik-Le Roux
D
D
Tropel
P
P
Roullot
V
V
Nurden
A
A
Marguerie
G
G
Nurden
P
P
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000201:enzymology* / Q000648:ultrastructure*; D002455:Cell Division; D015774:Ganciclovir / Q000494:pharmacology; D006410:Hematopoiesis / Q000187:drug effects / Q000235:genetics*; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000648:ultrastructure; D051379:Mice; D008822:Mice, Transgenic; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000187:drug effects / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000187:drug effects; D013921:Thrombocytopenia / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D013926:Thrombopoietin / Q000378:metabolism; D013937:Thymidine Kinase / Q000187:drug effects / Q000235:genetics*; D019076:Transgenes / Q000187:drug effects
D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D013926:Thrombopoietin; D013937:Thymidine Kinase; D015774:Ganciclovir